CompletedNot Applicable

Observational Study on the Use of Akynzeo® in Patients Receiving HEC

Canada207 participantsStarted 2018-10-03

Plain-language summary

This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology patients receiving highly emetogenic chemotherapy (HEC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient scheduled to receive a highly emetogenic chemotherapy (HEC).
✓. Patient scheduled to receive antiemetic prevention with Akynzeo® according to the approved Canadian Product Monograph as deemed medically necessary by the participating physician independently from this study.
✓. Age ≥ 18 years.
✓. Women of childbearing potential must use effective contraception during therapy and up to one month after treatment with Akynzeo®.
✓. Patient (and/or patient's authorized legal representative) should understand the nature of the study and provide written informed consent prior to or at the screening visit.
✓. Patient is able and willing to comply with the study protocol for the entire length of the study and will follow all study requirements, procedures and complete all visits as required.
✓. Patient is participating in another clinical trial where antiemetic treatment is not pre-specified by the study protocol.

Exclusion criteria

✕. Women of child bearing potential who are pregnant, planning on becoming pregnant or breast feeding.
✕. Hypersensitivity to active substances, excipients or other ingredients of Akynzeo®.
✕. Concomitant use of pimozide, terfenadine, astemizole, or cisapride.
✕. Patient currently enrolled in another clinical trial where antiemetic treatment is pre-specified by the study protocol.

What they're measuring

Total Functional Living Index-Emesis (FLIE) Score at Cycle 1

Timeframe: Day 5 of cycle 1

Trial details

NCT IDNCT03649230

SponsorPurdue Pharma, Canada

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-12-30

Results submitted2021-09-24

View on ClinicalTrials.gov More Chemotherapy-Induced Nausea and Vomiting trials